黑色素瘤患者抗PD-1抗体治疗超越RECIST进展的FDA汇总分析
该汇总分析纳入8项多中心临床试验的2624例接受抗PD-1抗体治疗的不可切除或转移性黑色素瘤患者,其中1361例出现RECIST进展,692例继续治疗超越进展。继续治疗可能适用于经特定标准筛选的进展患者。
要点
- RECIST进展后继续抗PD-1治疗,14%患者靶病灶负荷较进展时减少≥30%。
- 继续治疗需基于特定标准筛选患者,并权衡已知毒性谱。
核心结论
- 抗PD-1抗体治疗超越RECIST进展可能适用于经特定标准筛选的不可切除或转移性黑色素瘤患者。
- 产品标签未推荐超越进展继续治疗,因临床获益尚待证实。
研究设计与样本
- 汇总分析纳入8项多中心临床试验中接受至少一剂抗PD-1抗体治疗的不可切除或转移性黑色素瘤患者数据。
- 共纳入2624例接受免疫治疗的患者,其中1361例(52%)出现RECIST进展。
主要发现
- 692例(51%)进展后继续抗PD-1治疗,669例(49%)未继续。
- 继续治疗组中95例(19%)可评估患者靶病灶负荷较进展时减少≥30%,占继续治疗组的14%、全部免疫治疗患者的4%。
- 未继续治疗组669例中362例(54%)在停药后90天内发生严重不良事件,继续治疗组692例中295例(43%)。
- 停药后90天内免疫相关不良事件:继续治疗组78/692(11%),未继续治疗组106/669(16%)。
关键数值与推荐
- 超越进展反应定义为靶病灶肿瘤负荷(参考直径之和)较RECIST进展时减少至少30%,无需后续确认。
临床怎么用
- 对不可切除或转移性黑色素瘤患者,RECIST进展后可基于特定标准筛选适合继续抗PD-1治疗者。
- 继续治疗决策需结合潜在迟发反应可能性与已知毒性谱进行个体化权衡。
局限性
- 原文未报告统计分析方法和混杂因素控制等细节。
- 原文未报告继续治疗组与未继续治疗组基线特征的详细比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients who receive immunotherapeutic drugs might develop an atypical response pattern, wherein they initially meet conventional response criteria for progressive disease but later have decreases in tumour burden. Such responses warrant further investigation into the potential benefits and risks for patients who continue immunotherapy beyond disease progression defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. METHODS: For this pooled analysis, we included all submissions of trial reports and data to the US Food and Drug Administration (FDA) in support of marketing applications for anti-programmed death receptor-1 (PD-1) antibodies (alone or in combination) for the treatment of patients with unresectable or metastatic melanoma that allowed for continuation of the antibody beyond RECIST-defined progression in the anti-PD-1 group and were approved by FDA before Jan 1, 2017. To investigate the effect of treatment beyond progression in patients with metastatic melanoma and to better characterise which of these patients would benefit from extended treatment, we pooled individual patient data from patients who received at least one dose of an anti-PD-1 antibody in the included trials. We included any patient receiving the anti-PD-1 antibody after their RECIST-defined progression date in the treatment beyond progression cohort and analysed them descriptively at baseline and at time of progression versus the cohort not receiving treatment beyond progression. We analysed the target lesion response after progression in patients in the treatment beyond progression cohort relative to progressive disease and baseline target lesion burden. We defined a treatment beyond progression response as a decrease in target lesion tumour burden (sum of the reference diameters) of at least 30% from the burden at the time of RECIST-defined progression that did not require confirmation at a subsequent assessment. We also compared individual timepoint responses, overall survival, and adverse events in the treatment beyond progression versus no treatment beyond progression cohorts. FINDINGS: Among the eight multicentre clinical trials meeting this study's inclusion criteria, we pooled the data from 2624 patients receiving immunotherapy. 1361 (52%) had progressive disease, of whom 692 (51%) received continued anti-PD-1 antibody treatment beyond RECIST-defined progression and 669 (49%) did not. 95 (19%) of 500 patients in the treatment beyond progresssion cohort with evaluable assessments had a 30% or more decrease in tumour burden, when considering burden at RECIST-defined progression as the reference point, representing 14% of the 692 patients treated beyond progression and 4% of all 2624 patients treated with immunotherapy. Median overall survival in patients with RECIST-defined progressive disease given anti-PD-1 antibody was longer in the treatment beyond progression cohort (24·4 months, 95% CI 21·2-26·3) than in the cohort of patients who did not receive treatment beyond progression (11·2 months, 10·1-12·9). 362 (54%) of 669 patients in the no treatment beyond progression cohort had a serious adverse event up to 90 days after treatment discontinuation compared with 295 (43%) of 692 patients in the treatment beyond progression cohort. Immune-related adverse events that occurred up to 90 days from discontinuation were similar between the treatment beyond progression cohort (78 [11%] of 692 patients) and the no treatment beyond progression cohort (106 [16%] of 669). INTERPRETATION: Continuation of treatment beyond progression in the product labelling of these immunotherapies has not been recommended because the clinical benefit remains to be proven. Treatment beyond progression with anti-PD-1 antibody therapy might be appropriate for selected patients with unresectable or metastatic melanoma, identified by specific criteria at the time of progression, based on the potential for late responses in the setting of the known toxicity profile. FUNDING: None.
引用
- Beaver JA, Hazarika M, Mulkey F, et al. Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. Lancet Oncol. 2018. PMID: 29361469. doi:10.1016/S1470-2045(17)30846-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。